Neuraltus Pharmaceuticals, Inc., is currently enrolling up to 120 individuals with ALS and evidence of systemic inflammation in a second Phase 2 study of its investigational treatment NP001, an immune system regulator. California Pacific Medical Center's Dr. Robert Miller will discuss how inflammation is thought to be a contributing factor to ALS disease progression and existing NP001 data suggest that it may have an effect on inflammation in the immune system. This additional Phase 2 study is being conducted to test whether NP001 slows the progression of ALS symptoms in patients who have evidence of increased inflammatory activity in their blood.
